Seasonal variation of anti-PD-1 outcome in melanoma-Results from a Dutch patient cohort.


Journal

Pigment cell & melanoma research
ISSN: 1755-148X
Titre abrégé: Pigment Cell Melanoma Res
Pays: England
ID NLM: 101318927

Informations de publication

Date de publication:
08 Aug 2023
Historique:
revised: 09 06 2023
received: 28 02 2023
accepted: 22 07 2023
pubmed: 9 8 2023
medline: 9 8 2023
entrez: 9 8 2023
Statut: aheadofprint

Résumé

Despite the improved survival rates of patients with advanced stage melanoma since the introduction of ICIs, many patients do not have (long-term) benefit from these treatments. There is evidence that the exposome, an accumulation of host-extrinsic factors including environmental influences, could impact ICI response. Recently, a survival benefit was observed in patients with BRAF wild-type melanoma living in Denmark who initiated immunotherapy in summer as compared to winter. As the Netherlands lies in close geographical proximity to Denmark and has comparable seasonal differences, a Dutch validation cohort was established using data from our nationwide melanoma registry. In this study, we did not observe a similar seasonal difference in overall survival and are therefore unable to confirm the Danish findings. Validation of either the Dutch or Danish findings in (combined) patient cohorts from other countries would be necessary to determine whether this host-extrinsic factor influences the response to ICI-treatment.

Identifiants

pubmed: 37554041
doi: 10.1111/pcmr.13117
doi:

Types de publication

Letter

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2023 The Authors. Pigment Cell & Melanoma Research published by John Wiley & Sons Ltd.

Références

Danmark, K. (n.d.). Temperaturer, Hydrotermfigur, Klima borde til Danmark. Climate-Data.org. (Assessed on 02/nov/2022)
Davenport, E. R., Mizrahi-Man, O., Michelini, K., Barreiro, L. B., Ober, C., & Gilad, Y. (2014). Seasonal variation in human gut microbiome composition. PLoS One, 9, e90731.
Ellebaek, E., Schina, A., Schmidt, H., Haslund, C. A., Bastholt, L., Svane, I. M., & Donia, M. (2022). Seasonal variation in effect of anti-PD-1 initiation on overall survival among patients with advanced melanoma. Pigment Cell & Melanoma Research, 36, 224-231.
Jochems, A., Schouwenburg, M. G., Leeneman, B., Franken, M. G., van den Eertwegh, A. J. M., Haanen, J. B. A. G., Gelderblom, H., Uyl-de Groot, C. A., Aarts, M. J. B., van den Berkmortel, F. W. P. J., Blokx, W. A. M., Cardous-Ubbink, M. C., Groenewegen, G., de Groot, J. W. B., Hospers, G. A. P., Kapiteijn, E., Koornstra, R. H., Kruit, W. H., Louwman, M. W., … van der Hoeven, J. J. M. (2017). Dutch melanoma treatment registry: Quality assurance in the care of patients with metastatic melanoma in The Netherlands. European Journal of Cancer, 72, 156-165.
Koliada, A., Moseiko, V., Romanenko, M., Piven, L., Lushchak, O., Kryzhanovska, N., Guryanov, V., & Vaiserman, A. (2020). Seasonal variation in gut microbiota composition: Cross-sectional evidence from Ukrainian population. BMC Microbiology, 20, 100.
Miller, G. W., & Jones, D. P. (2014). The nature of nurture: Refining the definition of the exposome. Toxicological Sciences, 137, 1-2.
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021). Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell, 184, 5309-5337.
Moreira, A., Heinzerling, L., Bhardwaj, N., & Friedlander, P. (2021). Current melanoma treatments: Where do we stand? Cancers, 13, 221.
Royal Netherlands Meteorological Institute, Ministery of Infrastructure and Water Management. (n.d.). Klimatologie - Metingen en waarnemingen. (Assessed on 02/nov/2022).

Auteurs

J S W Borgers (JSW)

Department of Medical Oncology, Antoni van Leeuwenhoek-The Netherlands Cancer Institute, Amsterdam, The Netherlands.

F H Burgers (FH)

Department of Medical Oncology, Antoni van Leeuwenhoek-The Netherlands Cancer Institute, Amsterdam, The Netherlands.

A Schina (A)

National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.

O J Van Not (OJ)

Dutch Institute for Clinical Auditing, Leiden, The Netherlands.
Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.

A J M van den Eertwegh (AJM)

Department of Medical Oncology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands.

C U Blank (CU)

Department of Medical Oncology, Antoni van Leeuwenhoek-The Netherlands Cancer Institute, Amsterdam, The Netherlands.

M J B Aarts (MJB)

Department of Medical Oncology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands.

F W P J van den Berkmortel (FWPJ)

Department of Medical Oncology, Zuyderland Medical Centre, Sittard, The Netherlands.

J W B de Groot (JWB)

Isala Oncology Center, Zwolle, The Netherlands.

G A P Hospers (GAP)

Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.

E Kapiteijn (E)

Department of Medical Oncology, Leiden University Medical Centre, Leiden, The Netherlands.

D Piersma (D)

Department of Internal Medicine, Medisch Spectrum Twente, Enschede, The Netherlands.

R S van Rijn (RS)

Department of Internal Medicine, Medical Centre Leeuwarden, Leeuwarden, The Netherlands.

A M Stevense-den Boer (AMS)

Department of Internal Medicine, Amphia Hospital, Breda, The Netherlands.

A A M van der Veldt (AAM)

Department of Medical Oncology and Radiology & Nuclear Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands.

G Vreugdenhil (G)

Department of Internal Medicine, Maxima Medical Center, Veldhoven, The Netherlands.

M J Boers-Sonderen (MJ)

Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands.

M W J M Wouters (MWJM)

Dutch Institute for Clinical Auditing, Leiden, The Netherlands.
Department of Biomedical Data Sciences, Leiden University Medical Centre, Leiden, The Netherlands.
Department of Surgical Oncology, Antoni van Leeuwenhoek-The Netherlands Cancer Institute, Amsterdam, The Netherlands.

K P M Suijkerbuijk (KPM)

Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.

J V van Thienen (JV)

Department of Medical Oncology, Antoni van Leeuwenhoek-The Netherlands Cancer Institute, Amsterdam, The Netherlands.

J B A G Haanen (JBAG)

Department of Medical Oncology, Antoni van Leeuwenhoek-The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Classifications MeSH